Anti-Tumour Necrosis Factor-?? Therapy for Rheumatoid and Other Inflammatory Arthropathies
- 1 January 2006
- journal article
- review article
- Published by Springer Nature in Drugs & Aging
- Vol. 23 (11) , 855-860
Abstract
Anti-tumour necrosis factor (TNF)-α represents a major advance in the treatment of rheumatoid arthritis (RA), ankylosing spondylitis and psoriatic arthritis. It is usually well tolerated, but a...Keywords
This publication has 41 references indexed in Scilit:
- Anti-TNF Antibody Therapy in Rheumatoid Arthritis and the Risk of Serious Infections and MalignanciesJAMA, 2006
- Long term safety of etanercept in elderly subjects with rheumatic diseasesAnnals of the Rheumatic Diseases, 2006
- Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: Results of a double‐blind, randomized, placebo‐controlled trialArthritis & Rheumatism, 2005
- Survival and safety of treatment with infliximab in the elderly populationRheumatology, 2005
- Etanercept treatment of psoriatic arthritis: Safety, efficacy, and effect on disease progressionArthritis & Rheumatism, 2004
- Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti–tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: A randomized, placebo‐controlled, 52‐week trialArthritis & Rheumatism, 2004
- Eligibility of patients in routine care for major clinical trials of anti–tumor necrosis factor α agents in rheumatoid arthritisArthritis & Rheumatism, 2003
- Predictors of infection in rheumatoid arthritisArthritis & Rheumatism, 2002
- Peptostreptococcal pericarditis complicating anti-tumour necrosis factor α treatment in rheumatoid arthritisAnnals of the Rheumatic Diseases, 2002
- Summary of clinical trials in rheumatoid arthritis using infliximab, an anti-TNFα treatmentAnnals of the Rheumatic Diseases, 1999